Business Context and Reporting Period
This Form 8-K Current Report was filed by Compass Therapeutics, Inc. on February 22, 2022. The report discloses a corporate governance event regarding the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a personnel change and does not contain financial statements.
Material Changes
The material change reported is the resignation of Brett Kaplan, M.D., from the Board of Directors and all associated committees. The resignation became effective on February 25, 2022.
Management Commentary and Risks
Management explicitly stated that Dr. Kaplan's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies, or practices. No other risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the effective date of the resignation (February 25, 2022).
- Confirm the absence of any disagreement between the departing director and the company.
- Check subsequent filings for the appointment of a replacement director.